Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

J Clin Oncol. 2024 Feb 10;42(5):571-583. doi: 10.1200/JCO.23.00339. Epub 2023 Nov 14.

Abstract

Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.

Trial registration: ClinicalTrials.gov NCT02987543.

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Phthalazines / therapeutic use
  • Piperazines / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / genetics

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • olaparib
  • Phthalazines
  • Piperazines

Associated data

  • ClinicalTrials.gov/NCT02987543